Antoine Armand is due to visit Sanofi’s Doliprane production site in Lisieux (Calvados) on Monday morning with the Minister Delegate for Industry, Marc Ferracci.
:quality(50)/2023/07/06/64a68815cd1a7_placeholder-36b69ec8.png)
Published
Reading time: 1 min
:quality(50)/2024/10/13/075-widak-sanofi15241013-npk4x-670c1312ca349407912876.jpg)
He demands compensation. Sunday, October 13, the Minister of the Economy, Antoine Armand, affirmed that he would not refrain from blocking the sale of the Sanofi subsidiary producing Doliprane to the American investment fund CD&R if it is not guaranteed that the medicine continues to be produced in France. “My commitment is that Doliprane continues to be produced in France, by employees in France” And “we will have to ask for extremely strong guarantees”he declared on BFMTV.
He will be Monday morning with the Minister Delegate in charge of Industry, Marc Ferracci, at the Sanofi Doliprane production site in Lisieux (Calvados). Asked about a possibility of blocking the transfer, the minister replied that “we will ask for extremely strong guarantees likely to reassure both employees and the French in the medium term (…) and if this is not the case, nothing will seem forbidden to me at first glance”.
The minister must discuss Monday “with employees and their representatives of these guarantees, of these conditions because producing Doliprane in France is our industrial and sovereign and health strategy and it must remain so”he said. The announcement of the passage of the best-selling drug in France under the American flag raised eyebrows among politicians of all stripes, some of whom urged the government to block this operation, in the name of French health sovereignty.